Potential interactions between psychotropic drugs and alcohol and tobacco dependence
DOI:
https://doi.org/10.1590/s2175-97902022e20401Keywords:
Alcoholism, Drug interactions, Pharmacoepidemiology, Tobacco use disorder, Substance-related disordersAbstract
The aim of this study was to identify and analyze the potential interactions between psychotropic drugs and alcohol and tobacco addiction. A cross-sectional study was carried out on secondary data collection in a Center for Psychosocial Care in Alcohol and Other Drugs. Subjects aged 18 years old and over, with alcohol and tobacco dependence, who were taking psychotherapies were included. Medical records with the most recent prescriptions were reviewed. Potential interactions between psychotropic drugs and alcohol and tobacco were analyzed using the Micromedex database and stratified according to clinical risks and mechanisms of action. The Pearson’s Chi-square test was used to find significant associations between the variables of interest. The significance level was set at 5%. Between the 2010-2018 period, 2,322 subjects were treated at the care center. Of these, 1,020 fulfilled the inclusion criteria, out of whom 515 (50.5%) were dependent on alcohol and 310 (30.4%) were dependent on tobacco. We found 1,099 potential interactions between psychotropic drugs and alcohol and 160 potential interactions between psychotropic drugs and tobacco. In relation to alcohol dependence, psychotropic drugs interacted largely with moderate clinical risk, and pharmacokinetic mechanisms of action. In relation to tobacco dependence, high clinical risk interactions and pharmacodynamic mechanisms of action predominated.
Downloads
References
Almeida DERG, Andrade ALM, Cruz FD, Micheli D. Perception of freedom in leisure among substance users and nonusers. Psico-USF. 2018;23(1):13-24.
Alvim MM, Da Silva LA, Leite ICG, Silvério MS. Adverse events caused by potential drug-drug interactions in an intensive care unit of a teaching hospital. Rev Bras Ter Intensiva. 2015;27(4):353-9.
Antonelli M, Ferrulli A, Sestito L, Vassallo GA, Tarli C, Mosoni C et al. Alcohol addiction - the safety of available approved treatment options. Expert Opinion on Drug Safety. 2017;17(2):169-177.
Becker HC. Alcohol dependence, withdrawal, and relapse. Alcohol Res Health. 2008;31(4):348-361.
Bezerra IC, Morais JB De, Paula ML De, Silva TMR, Jorge MSB. The use of psychotropic drugs in psychosocial care: an analysis in the light of care management. Saúde Debate. 2016;40(110):148-61.
Cedraz SJ, Junior MC dos S. Identification and characterization of drug interactions in prescriptions of the intensive care unit of a public hospital in the city of Feira de Santana, BA. Rev Soc Bras Clin Med. 2014;55(75):1-7.
Cruciol-Souza JM, Thomson JC. A pharmacoepidemiologic study of drug interactions in a Brazilian teaching hospital. Clinics. 2006;61(6):515-20.
Dawson DA, Goldstein RB, Saha TD, Grant BF. Changes in alcohol consumption: United States, 2001-2002 to 2012-2013. Drug Alcohol Depend. 2015;148(1):56-61.
Frey R, Becker C, Saleh S, Unger S, Van der Mey D, Mück W. Clinical pharmacokinetic and pharmacodynamic profile of riociguat. Clin Pharmacokinet. 2018;57(1):647-661
Guerzoni S, Pellesi L, Pini LA, Caputo F. Drug-drug interactions in the treatment for alcohol use disorders: A comprehensive review. Pharmacol Res. 2018;133(1):65-76.
Guglielmo R, Martinotti G, Quatrale M, Ioime L, Kadilli I, Di Nicola M et al. Topiramate in alcohol use disorders: review and update. CNS Drugs. 2015;29(5):383-95.
Guimarães RA, Souza MM, Caetano KAA, Teles SA, Matos MA. Use of illicit drugs by adolescents and young adults of an urban settlement in Brazil. Rev Asssociação Médica Bras. 2018;64(July 2014):114-8.
Iyer SV, Harpaz R, LePendu P, Bauer-Mehren A, Shah NH. Mining clinical text for signals of adverse drug-drug interactions. J Am Med Informatics Assoc. 2014;21(2):353-62.
Johnson JE, Gibbons MBC, Crits-Christoph P. Gender, Race, and group behavior in group drug treatment. Drug Alcohol Depend . 2011;119(3):1-15.
Livingston M, Dietze P. National survey data can be used to measure trends in population alcohol consumption in Australia. Aust N Z J Public Health. 2016;40(3):233-5.
Maideen NMP. Tobacco smoking and its drug interactions with comedications involving CYP and UGT enzymes and nicotine. World J Pharmacol. 2019;8(2):14-25.
McLaughlin I, Dani JA, Biasi M. Nicotine withdrawal. Curr Top Behav Neurosci. 2015;24(1):99-123.
Mirra AP, Meirelles RHS, Godoy I de, Issa J, Reichert J, Carvalho NB et al. Focus guidelines - smoking part I. Rev Assoc Med Bras. 2010;56(2):127-43.
Moura C, Acurcio F, Belo N. Drug-drug interactions associated with length of stay and cost of hospitalization. J Pharm Pharm Sci. 2009;12(3):266-72.
Munhoz TN, Santos IS, Nunes BP, Mola CL de, Silva ICM da, Matijasevich A. Trends in alcohol abuse in Brazilian state capitals from 2006 to 2013: an analysis of data from the VIGITEL survey. Reports Public Heal. 2017;33(7):1-11.
Pan American Health Organization. The importance of phamacovigilance. Vol. 4, Pan American Health Organization. 2005. 48 p.
Redonnet B, Chollet A, Fombonne E, Bowes L. Tobacco, alcohol, cannabis and other illegal drug use among young adults: the socioeconomic context. Drug Alcohol Depend . 2012;121(3):231-9.
Rosa MI da, Caciatori JFF, Panatto APR, Silva BR, Pandini JC, Freitas LBS de, et al. Tobacco use and associated factors among students of a university of Criciúma (SC). Cad Saúde Coletiva. 2014;22(1):25-31.
Santos MM dos, Cabra S de MR, Mascarenhas MDM, Santos RM dos, Eulálio JML. Overweight and the use of psychiatric drugs in patients with mental disorders attended at psychosocial care center in Teresina, Piauí, Brazil. Nutr Hosp. 2016;33(4):838-41.
Silva M de NRM de O, Abbad G da S, Montezano L. Practices and therapeutic strategies of the psychosocial care centers alcohol and drugs. Paidéia. 2019;29(1):1-9.
Skogen JC, Sivertsen B, Lundervold AJ, Stormark KM, Jakobsen R, Hysing M. Alcohol and drug use among adolescents: and the co-occurrence of mental health problems. Ung@hordaland, a population-based study. BMJ Open. 2014;4(9):1-10.
Stanciu CN, Penders TM, Wuensch KL, Davis J, Elnaga K. Underutilization of pharmacotherapy for treatment of alcohol use disorders part II-results from a survey of practices among North Carolina Mental Health Providers and Brief Review of Efficacy of Available Pharmacotherapies. J Alcohol Drug Depend. 2017;5(5):1-7.
Takayanagi Y, Spira AP, Roth KB, Gallo JJ, Eaton WW, Mojtabai R. Accuracy of reports of lifetime mental and physical disorders: Results from the baltimore epidemiological catchment area study. JAMA Psychiatry. 2014;71(3):273-80.
Voskoboinik A, Kalman JM, De Silva A, Nicholls T, Costello B, Nanayakkara S et al. Alcohol Abstinence in Drinkers with Atrial Fibrillation. N Engl J Med. 2020;382(1):20-28.
Weintraub SJ. Diazepam in the treatment of moderate to severe alcohol withdrawal. CNS Drugs . 2017;31(1):87-95.
Wehring HJ, Heishman SJ, McMahon RP, Liu F, Feldman S, Raley H et al. Antipsychotic treatment and tobacco craving in people with schizophrenia. J Dual Diagn. 2017;13(1):36-42.
World Health Organization. WHO Report on the Global Tobacco Epidemic, 2008: the MPOWER package. World Health Organization. 2008. 330 p.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on-line journal has open and free access.
